Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Common Equity: 2009-2024

Historic Common Equity for Northwest Biotherapeutics (NWBO) over the last 16 years, with Dec 2024 value amounting to -$94.5 million.

  • Northwest Biotherapeutics' Common Equity fell 35.61% to -$108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.6 million, marking a year-over-year decrease of 35.61%. This contributed to the annual value of -$94.5 million for FY2024, which is 43.66% down from last year.
  • As of FY2024, Northwest Biotherapeutics' Common Equity stood at -$94.5 million, which was down 43.66% from -$65.8 million recorded in FY2023.
  • Northwest Biotherapeutics' Common Equity's 5-year high stood at -$65.8 million during FY2023, with a 5-year trough of -$362.9 million in FY2020.
  • Over the past 3 years, Northwest Biotherapeutics' median Common Equity value was -$94.5 million (recorded in 2024), while the average stood at -$96.1 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Common Equity tumbled by 705.57% in 2020, and later surged by 65.84% in 2021.
  • Northwest Biotherapeutics' Common Equity (Yearly) stood at -$362.9 million in 2020, then skyrocketed by 65.84% to -$124.0 million in 2021, then declined by 3.32% to -$128.1 million in 2022, then surged by 48.66% to -$65.8 million in 2023, then tumbled by 43.66% to -$94.5 million in 2024.